Exploring a Novel Mechanism of Action with the Development of TCR– PD-1 Agonist Bispecifics for the Treatment of Autoimmune Diseases

4:00 pm - Wednesday 8th July 2026

  • Aiming to deliver tissue-specific TCR-based therapeutics
  • Adapting the ImmTAC platform with a novel effector function to address autoimmune diseases
  • Exploring the development of a beta-cell–targeted immune-suppressive PD-1 agonist bispecific to treat type I diabetes

Speakers:

Annelise vuidepot
Senior Vice President Chief Technology Officer - Head of Pipeline and Platform Research and UK Site Head
Immunocore